Introduction
Cerebrospinal fluid (CSF) proteins, considered to be markers of the 2 key neuropathological constituents of Alzheimers's disease (AD), amyloid plaques and neurofibrillay tangles (NFT), have been found to differentiate a diagnosis of AD [1] , to predict progression from mild cognitive impairment to AD [1] , the rate of decline in mild cognitive impairment [2] and mortality [3] . However, previous reports have largely neglected the equally important question whether biomarkers are associated with neuropsychiatric symptoms and the rate of decline in subjects with dementia.
The rate of progression of AD is highly variable among individuals [4] . Both genes [4] and a variety of clinical variables, including hallucinations [5] , psychosis [6] , depression [7] and agitation [8] , have been found to be related to the rate of decline. Similarly, neuropsychiatric symptoms, in particular depression and apathy, have been found to be associated with the decline in those with pre-clinical AD [9] . Although brain autopsy is the only method to confirm neuritic plaques and NFT conclusively, an overall clinical picture provides substantial information to predict the likelihood of key morphological changes to become evident as the disease progresses. Few studies have explored the clinical correlates of morphological changes in AD, but agitation [10] , apathy [11] and psychosis [12] have been found to be associated with NFT pathology in AD. In addition, patients with Lewy body dementia with clinical symptoms resembling AD have a more severe NFT pathology compared to those with atypical dementia with Lewy body phenotype [13] .
Exploring the relationship between CSF biomarkers and neuropsychiatric symptoms is important, since these symptoms have major clinical impact [14] and may be clinical markers of rapid decline, and the treatment options are limited, with a clear need to develop novel drug therapies [15] . Knowledge of the relationship between CSF biomarkers and neuropsychiatric symptoms might contribute to the understanding of the neurobiological underpinnings of these symptoms and thus inform the development of novel drugs as well as providing an important opportunity to monitor disease progression and treatment effect.
The aim of this study therefore was to explore the relationship between CSF biomarkers in people with early AD and neuropsychiatric features found to be associated with the rate of progression, i.e. psychosis, agitation, apathy and depression.
Methods

Subjects
Patients with AD from the first 50 individuals who consented to lumbar puncture were recruited from a clinical cohort study of subjects with mild dementia (Mini-Mental State Examination score of 20 or higher) who were referred to the outpatient clinics of neurology, geriatric medicine and old-age psychiatry in the Hordaland and Rogaland counties in western Norway. All participating subjects provided written informed consent after the procedure had been fully explained to them, and the study was approved by the Regional Committee for Medical Research Ethics in Western Norway.
Clinical Assessments
The patients were examined by an experienced clinician (board-certified specialist in psychiatry, neurology or geriatric medicine) and a research nurse. Prior to the study, the study clinicians and nurses participated in several training sessions on the use of diagnostic and clinical rating scales. Standardised diagnostic criteria for AD were applied (NINCDS-ADRDA) [16] , based on history, physical examination and a detailed neuropsychiatric assessment. A standardised instrument to verify a history of cognitive decline was employed by asking the caregivers to complete the IQ Code [17] . The cognitive assessment included the MiniMental State Examination and measures of verbal memory, visuospatial, executive and language functions. Blood tests and MRI of the brain were performed.
Neuropsychiatric Assessment
The Neuropsychiatric Inventory (NPI) [18] was used to assess psychosis with the NPI-3 subscale, including the 3 items delusions, hallucinations and agitation (all scored 0-12). Depression was rated using a clinical interview, the Montgomery and Aasberg Depression Rating Scale [10 items, from 0 (not present) to 6 (maximum severity)] [19] , and apathy using the Apathy Scale [14 items, scored from 0 (not at all) to 3 (maximum severity)] [20] .
Sampling and Storage of CSF CSF samples were obtained by lumbar puncture between 7 and 10 a.m., the patient fasting from midnight at the latest. The samples were kept on ice and immediately sent to the laboratory where they were routinely assayed for cell counts, levels of glucose and protein to exclude relevant CSF abnormalities. Thus, the first 3-4 ml were used for routine analyses. Study samples were collected in polypropylene tubes, centrifuged at 2,000 g for 10 min, and supernatants were aliquoted into new polypropylene tubes and stored at -80 ° C until assessment.
Enzyme-Linked Immunosorbent Assays
Total tau protein and tau phosphorylated at threonine 181 (Ptau) were measured using the Innotest hTau and Innotest Phospho-Tau (181) immunoassays, commercially available kits manufactured by Innogenetics (Ghent, Belgium), and A ␤ 1-42 was determined with the enzyme-linked immunosorbent assay kit from Biosource Europe S.A. These assays are done based on enzyme linked immunosorbent assays, with a capture antibody bound on a solid phase. The tests were performed following the manufacturer protocol.
For A ␤ 1-42 , the standard range was 15.63-1,000 pg/ml, limit of detection was ! 10 pg/ml. Intra-assay precision CV ϳ 3%, Interassay Precision CV ! 5.5%.
For Tau, standard range was 75-1,200 pg/ml and the limit of detection 59.3 pg/ml. The intra-assay precision ranged from 1.2 to 5.9 % CV and the inter-assay precision from 1.7 to 6.0 % CV. For p-tau, the standard range was 15.6-500 pg/ml, and the limit of detection was 15.6 pg/ml. The intra-assay precision was ! 5 % CV and the inter-assay precision (% CV) ! 10 % CV.
Statistics
The CSF biomarkers were not normally distributed, and the associations between clinical outcome measures and CSF markers were thus analysed using Spearman correlations. A p value ! 0.05 was considered statistically significant.
Results
Thirty-two patients (71% female) had AD and were included, with a mean age of 73.9 years (SD = 9.0), a MiniMental State Examination score of 24.2 (SD = 2.3) and a duration of disease of 2.1 years (SD = 1.1). The apathy score was significantly correlated with tau and p-tau but not with A ␤ 1-42 ( table 1 , fig. 1 ). There were no significant relationship between depression or psychosis/agitation composite scores and any of the CSF biomarkers. Similarly, no significant correlations were found when analysing the 3 NPI-3 items separately (data not shown).
Discussion
We examined for the first time the association of CSF A ␤ 1-42 , tau and p-tau with neuropsychiatric symptoms. Neuropsychiatric symptoms such as depression, psychosis, agitation and apathy in patients with mild AD have been reported to predict a more rapid decline in AD. In this study an association was found between severity of apathy and increased tau and p-tau, but there were no relationships between concentrations of CSF biomarkers and depression or psychosis. These findings support the hypothesis that apathy, but not depression or psychosis, is associated with the burden of NFT in patients with mild AD.
The aetiology of apathy in AD is not clear. However, a recent structural imaging study reported a strong association between apathy and medial frontal atrophy [21] , and 2 clinicopathologic investigations found apathy to be linked to burden of NFT in the same region [10, 11] . These findings are consistent with the association between apathy and tau and p-tau in the current study. Still, since our findings are based on a small sample, they should be interpreted cautiously and need to be replicated in larger studies.
Neurochemical changes including dopaminergic and cholinergic deficits may also contribute to apathy in addition to morphological changes. Gene studies indicate that dopaminergic, noradrenergic, serotonergic and cholinergic changes may be associated with other neuropsychiatric symptoms in AD [22] . Functional studies have reported apathy to be related to reduced cingulate metabolic activity and perfusion [23, 24] . Finally, other pathological alterations such as subcortical vascular changes may also contribute to apathy.
The CSF level of p-tau is usually considered to reflect the phosphorylation state of tau, and thus the formation of tangles in AD, whereas the level of total tau is mostly thought to reflect the intensity of neuronal damage and degeneration [25] . However, few studies have explored this. An association of total tau with NFT was supported in 1 study [26] , and in another evaluation p-tau phosphorylated at threonin 231 was positively correlated with NFT in several cortical areas [27] . Two recent studies failed to find a relationship between total tau and p-tau and tangle burden in patients with AD [28, 29] . Autopsy studies are usually based on end-stage disease, and thus this finding does not preclude a close relationship between CSF tau and NFT pathology earlier in the disease.
Neuropsychiatric symptoms such as depression and psychosis may be more closely related to neurochemical changes or pathologies other than NFT and amyloid plaques, such as synaptic or neuronal loss, Lewy bodies or vascular changes. This explanation is supported by our previous finding that in patients with dementia with Lewy bodies, visual hallucinations were associated with less NFT but more Lewy body pathology [13] . Alternatively, the location of the lesions may be more relevant than the type. The observed lack of a link between depression and psychosis and CSF markers may be related to low statistical power due to a small sample size. The patients were not selectively recruited for neuropsychiatric morbidity, and thus the frequency and severity of such symptoms was rather low, not surprising given the mild stage of dementia. For example, only 13% of the subjects had clinically significant delusional symptoms, i.e. an NPI score 1 3. Finally, we explored the relationship in subjects with AD only, and thus it is possible that associations between CSF biomarkers and depression and psychosis exist in patients with other diagnoses of dementia. This should be explored in further research.
In summary, in this study, we found a relationship between apathy and the levels of CSF tau and p-tau, indicating that apathy is at least partly associated with the NFT burden even in early AD. Other neuropsychiatric symptoms such as depression and psychosis were not linked to the CSF biomarkers A ␤ 1-42 , tau or p-tau, suggesting that brain changes other than NFT and amyloid plaques are the key underlying mechanisms for such symptoms in AD. Our findings raise the possibility that depression and psychosis are more amenable to drug therapies than apathy and cognitive and functional changes, which are more closely related to morphological variation. Further studies of how CSF biomarkers relate to longitudinal course and clinical correlates are warranted, both in AD and in patients with other dementias.
